Actinium Pharmaceuticals, Inc. ATNM
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +8.82%
- 1 year
- +4.23%
- Open
- 1.51
- Prev close
- 1.53
- Mkt cap
- 46.53M
- Vol
- 157.41K
- Avg vol
- 188.97K
- EPS
- 0.36
- P/E
- 4.11
- Div yield
- 0.00%
More statistics
- Low
- 1.45
- High
- 1.54
- Forward P/E
- -1.77
- Beta
- 0.15
- Short ratio
- 5.72
- Inst. own
- 30.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.55
- 200-d avg
- 4.86
- 1y target
- 5.00
News
2 days ago prnewswire.com
Actinium Pharmaceuticals Announces Inducement Grant to New Employee
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an…
4 days ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
-
1 week ago benzinga.com
Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy…
1 week ago benzinga.com
Why Is Actinium Pharmaceuticals Stock Gaining Tuesday?
Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.
-
1 week ago benzinga.com
Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new…
1 week ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
-
1 week ago benzinga.com
Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to…
-
2 weeks ago benzinga.com
Actinium Pharma To Present Preclinical Data Supporting ATNM-400's Broad Potential At 39th Annual Congress Of EANM
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal…
-
2 weeks ago benzinga.com
Actinium Pharmaceuticals To Present Early Phase 1 Clinical Data For ATNM-400 In Metastatic Prostate Cancer At EANM 2026
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation…
-
2 weeks ago benzinga.com
Actinium Pharmaceuticals Appoints Dr. Matt David As CFO
Dr. David brings more than two decades of experience across biopharmaceutical operating leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc.…